FDA denies a petition to exempt certain radiology AI software from 510(k) review, stressing ongoing regulatory oversight.
Key Details
- 1FDA rejected Harrison.ai's petition seeking 510(k) exemption for four types of radiology AI (CADx, CADe, CADt, CADe/x) under specific classifications.
- 2At least 255 radiology AI devices received 510(k) clearance in 2025 alone, per FDA records.
- 3FDA clarified prior clearance does not guarantee manufacturer competence for future device development.
- 4Manufacturer-proposed self-evaluation and risk plans were dismissed due to insufficient FDA oversight mechanisms.
- 5Most public comments opposed the exemption, and FDA detailed significant differences between CADe, CADx, and CADe/x devices impacting regulatory needs.
- 6The agency emphasized vulnerabilities in relying on end-users (radiologists) to catch all performance issues.
Why It Matters
This decision underscores the FDA’s commitment to robust regulatory oversight for radiology AI, potentially affecting product development timelines and market strategies. The nuanced treatment of different device categories and the rejection of broad user detection arguments highlight stringent evidentiary requirements that developers must meet.
Source
AuntMinnie
Related News
•Radiology Business
UCLA Review Evaluates Breast AI for Early Cancer Detection
A UCLA-led review analyzes current evidence for AI tools in screening mammography, focusing on their capability to detect interval cancers.
•Radiology Business
Vara's AI Gains World's First Approval for Radiologist-Free Mammogram Triage
Vara has secured the world's first regulatory approval for an AI tool that autonomously classifies certain mammograms as normal, bypassing radiologist review.
•Radiology Business
Radiology Partners Urges FDA for Clarity on Imaging AI Regulations
Radiology Partners and Mosaic Clinical Technologies petition the FDA for clearer regulatory guidelines on imaging AI vision-language models.